RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals
"The first half of 2024 shows how the industry has learned to execute accretive deals ... ” the recent PwC report’s authors concluded.
ONCY's pelareorep fits both the accretive and novel therapeutic approval value proposition check-offs that Big Pharma says it is looking in an acquisition deal.
This nothwithstanding Big Pharma has been increasingly moving upstream in the R&D and innovation continuum, due to the lack of available assets in the form of late-stage clinical development biotech companies like ONCY, and have moved towards both pre-clinical and Phase 1 assets, as part of their current acquisition strategies.